Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men aged 18 or older who have been diagnosed with high-risk prostate cancer within the last 6 months
- The cancer must meet at least one of these high-risk features: a tumour that has grown beyond the prostate (found during a physical exam), an aggressive cancer grade (Grade 4 or higher), or a PSA blood test result of 20 or above
- People whose cancer involves nearby lymph nodes, either based on medical guidelines recommending lymph node radiation, or up to 4 suspicious lymph nodes seen on imaging
Who may not be able to join:
- People who have previously had radiation therapy to the pelvic area
- People who had a TURP procedure (a surgery to remove part of the prostate) less than 3 months ago
- People who have already had the prostate removed or received another primary treatment for prostate cancer, such as HIFU or cryotherapy
- People who cannot have an MRI scan for any reason
- People whose MRI scan does not show a visible area in the prostate that can be targeted for treatment
- People who have not had a PSMA-PET scan (a specific type of imaging scan for prostate cancer)
- People with inflammatory bowel disease
- People whose cancer has spread to other parts of the body (stage M1)
- People with a PSA blood test result above 50
- People considered unsuitable for the types of radiation therapy used in this trial (confirm with trial site)
- People who have had a history of any other cancer, except for a type of minor skin cancer called basal cell carcinoma
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Leonard P Bokhorst, MD, PhD, Haaglanden Medical Centre
Phone: 0031889792357
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Biochemical recurrence free survival; Late gastrointestinal and genito-urinary toxicity, and erectile dysfunction
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.